2026 ICD-10-CM Diagnosis Code T37.5X6AUnderdosing of antiviral drugs, initial encounter

ICD-10-CM CodesS00–T88T36-T50T37

ICD-10-CM T37.5X6A
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T37.5X6A is a billable ICD-10-CM diagnosis code for underdosing of antiviral drugs, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Underdosing of drugs and medicaments, initial encounter.

Code Identity

ICD-10-CM Code
T37.5X6A
Billable Status
Yes — Valid for Submission
Code Describes
Underdosing of antiviral drugs, initial encounter
Short Description
Underdosing of antiviral drugs, initial encounter
Same as the full description in the CMS dataset.
Parent Code
Underdosing of antiviral drugs

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT37Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics
This CodeT37.5X6AUnderdosing of antiviral drugs, initial encounter

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T37.5X6A.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Coding GuidelinesGuidance

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics (T37). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ029
Underdosing of drugs and medicaments, initial encounter
Default principal diagnosis: inpatient No · outpatient No

Clinical InformationClinical

  • Acyclovir

    a guanosine analog that acts as an antimetabolite. viruses are especially susceptible. used especially against herpes.
  • Valacyclovir

    a prodrug of acyclovir that is used in the treatment of herpes zoster and herpes simplex virus infection of the skin and mucous membranes, including genital herpes.
  • Inosine Pranobex

    an alkylamino-alcohol complex of inosine used in the treatment of a variety of viral infections. unlike other antiviral agents, it acts by modifying or stimulating cell-mediated immune processes rather than acting on the virus directly.
  • Methisazone

    an antiviral agent effective against pox viruses.
  • Ribavirin

    a nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both rna and dna viruses.
  • Rimantadine

    an rna synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
  • Thymopentin

    synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone. it is an immunomodulator which has been studied for possible use in the treatment of rheumatoid arthritis, aids, and other primary immunodeficiencies.
  • Trifluridine

    an antiviral derivative of thymidine used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. (from martindale, the extra pharmacopoeia, 30th ed, p557)
  • Vidarabine

    a nucleoside antibiotic isolated from streptomyces antibioticus. it has some antineoplastic properties and has broad spectrum activity against dna viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the vaccinia virus and varicella zoster virus.
  • Vidarabine Phosphate

    an adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. it is the monophosphate ester of vidarabine with antiviral and possibly antineoplastic properties.
  • Zalcitabine

    a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. this modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. the compound is a potent inhibitor of hiv replication at low concentrations, acting as a chain-terminator of viral dna by binding to reverse transcriptase. its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
  • Zidovudine

    a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. this modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. the compound is a potent inhibitor of hiv replication, acting as a chain-terminator of viral dna during reverse transcription. it improves immunologic function, partially reverses the hiv-induced neurological dysfunction, and improves certain other clinical abnormalities associated with aids. its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
ABOBT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
AciclovirT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
AcyclovirT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Antiviral drug NECT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Antiviral drug NEC::eyeT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Ara-AT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
AzidothymidineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
AZTT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
DideoxycytidineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
DideoxyinosineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
FlumidinT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Foscarnet sodiumT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Fosfonet sodiumT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Ganciclovir (sodium)T37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
IbacitabineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Inosine pranobexT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
Interferon (alpha) (beta) (gamma)T37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
MethisazoneT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
MethisoprinolT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
MetisazoneT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
MoroxydineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
RibavirinT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
RimantadineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
ThymopentinT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
TrifluridineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
TromantadineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
VidarabineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
VirugonT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
ZalcitabineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6
ZidovudineT37.5X1T37.5X2T37.5X3T37.5X4T37.5X5T37.5X6

Patient EducationClinical

Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T37.5X6A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
No Map There is no ICD-9 equivalent for this code.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T37.5X6AOverview

Is T37.5X6A (Underdosing of antiviral drugs) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report underdosing of antiviral drugs, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character A in T37.5X6A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for underdosing of antiviral drugs, such as an emergency visit or first evaluation.

Can T37.5X6A be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because underdosing of antiviral drugs, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.